Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Prenetics Sells ACT Genomics to Delta Electronics in Deal Valued Up to $71.78 Million
_↗ ir.prenetics.com
News Image

Prenetics Global Limited has strategically divested its majority stake in ACT Genomics for approximately $46 million in cash, significantly bolstering its pro-forma cash reserves to $86 million and total short-term assets to $117 million, while maintaining a debt-free balance sheet. This move completes Prenetics' business transformation, allowing the company to simplify its investment focus on high-growth consumer health brands like IM8, CircleDNA, and Europa. This strategic pivot has already yielded strong results, with the company raising its FY2025 revenue outlook to $80-$100 million (excluding ACT Genomics), primarily driven by the exceptional performance of IM8, which has rapidly acquired over 55,000 customers and achieved a 91% subscription rate. Additionally, Prenetics retains a valuable $70 million stake in early cancer detection company Insighta and plans to explore innovative treasury management strategies, including digital asset adoption.

Log In
Sign Up